Sphere Medical : Grant of Options

Sphere Medical Holding plc



For Immediate Release                                                                                  6 June 2014

Sphere Medical Holding plc

Grant of Options

Cambridge, UK, 6 June 2014: Sphere Medical Holding plc (AIM: SPHR.L) ("Sphere Medical" or the "Company") , a leading developer of innovative monitoring and diagnostic products for the critical care setting, has today granted share options as follows:

Director                                           No. of share options             Exercise price

Dr. Wolfgang Rencken, CEO            1,320,000 (note 1)                  40 pence

Matthew Hall, CFO                            275,000 (note 2)                     40 pence

Notes

1.   Wolfgang Rencken - 625,000 share options were issued under the Company's Enterprise Management Incentive Scheme and 695,000 share options were issued under the Company's Unapproved Share Option Scheme.

2.   Matthew Hall - 275,000 share options were issued under the Company's Enterprise Management Incentive Scheme.

All share options referred to are exercisable over ordinary shares of 1 pence each in the share capital of the Company ("Ordinary Shares"). 

These share options are subject to vesting conditions, a minimum holding period of five years from grant and have been issued at a premium of 48.1% to the 27 pence per Ordinary Share being the closing mid-market price for the Ordinary Shares on
5 June 2014.  The issue of these share options has been approved by the Company's Remuneration Committee.

For further information, please contact:

Sphere Medical Holding plc	Tel: [phone]
Dr. Wolfgang Rencken, Chief Executive Officer
Matthew Hall, Chief Financial Officer
Peel Hunt LLP	Tel: [phone]
James Steel
Clare Terlouw
Jock Maxwell Macdonald
finnCap	Tel: [phone]
Geoff Nash / Simon Hicks
Stephen Norcross
Consilium Strategic Communications	Tel: [phone]
Mary-Jane Elliott	[e-mail]
Amber Bielecka
Matthew Neal
Ivar Milligan

Notes for Editors

Sphere Medical (AIM: SPHR.L), is a medical device company developing a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.

Sphere Medical's products deliver real time analysis of blood gases, electrolytes and drug levels with laboratory accuracy, at the patient's bedside.  Sphere Medical's products can be used in a wide range of medical applications, enabling faster clinical decision making and improved patient outcomes, whilst reducing costs for healthcare payers.

Sphere Medical has entered into a collaboration agreement entered with Ortho-Clinical Diagnostics, Inc. for the development of Proxima and enhancement of Sphere's operational and production capabilities.

Sphere Medical has a number of partnerships with industry leading medical device companies and has received a strategic investment from Johnson & Johnson Development Corporation.

This information is provided by RNS

The company news service from the London Stock Exchange

ENDRDSXQLFBZQFEBBV